Taysha is now retrenching and focusing on another experimental drug, TSHA-102, for a rare neurological disorder called Rett Syndrome. The company now expects to reduce operating expenses enough to extend its cash runway into the fourth quarter of 2025.
While TSHA-120 was Taysha’s most advanced program, investors are most focused on the Rett Syndrome therapy, Cantor Fitzgerald analyst Kristen Kluska wrote in a note to clients. The company’s shares, which had dropped below $1, began climbing in August after the release of early results for TSHA-102 and a private placement financing of $150 million.
